Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Semaglutide oral - Novo Nordisk

Next Previous
Drug Profile

Semaglutide oral - Novo Nordisk

Alternative Names: GLP-1-SNAC; NN 6535; NN 9932; NN-9924; NNC0113-0217; OG-217SC; Rybelsus; Semagutide

Latest Information Update: 08 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antidementias; Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Alzheimer's disease; Obesity

Most Recent Events

  • 26 Feb 2024 Novo Nordisk Withdrawn prior enrollment a phase III trial in Type 2 diabetes mellitus (Treatment-naïve, Newly diagnosed, In adults) in US, Brazil, Bulgaria, Croatia, Greece, Hungary, India, Malaysia, Mexico, Poland, Romania, Serbia, and Thailand due to internal reprioritization (NCT06083675)
  • 16 Oct 2023 Novo Nordisk plans a phase III trial for Type 2 diabetes mellitus (Treatment-naïve, Newly diagnosed, In adults) in USA, Brazil, Bulgaria, Croatia, Greece, Hungary, India, Malaysia, Poland, Romania, Serbia, Thailand (PO) in January 2024 (NCT06083675)
  • 02 Oct 2023 Efficacy data from the phase III SUSTAIN trial in Type 2 diabetes mellitus presented at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top